How to Get Low-Dose Naltrexone in Colorado

What Low-Dose Naltrexone Actually Is

Low-dose naltrexone refers to naltrexone hydrochloride taken at 1.5 to 4.5 mg per night, roughly one-tenth of the 50 mg dose the FDA approved in 1984 for opioid and alcohol use disorder [1]. At these sub-pharmacological doses the drug transiently blocks opioid receptors for only 4 to 6 hours, which is thought to trigger a rebound upregulation of endogenous opioid signaling and reduce microglial activation in the central nervous system [2].

Naltrexone itself is FDA-approved and available as a brand-name tablet (ReVia) or extended-release injectable (Vivitrol). Neither formulation produces the 1.5 to 4.5 mg dose range used in LDN protocols. That gap is why every LDN prescription in Colorado, and nationally, must be filled by a 503A compounding pharmacy rather than a retail chain like Walgreens or CVS [3]. The FDA has not approved any compounded LDN product, meaning the off-label status creates real regulatory constraints that patients must understand before starting.

The proposed mechanism centers on transient opioid-receptor blockade triggering compensatory increases in beta-endorphin and met-enkephalin production [4]. A secondary pathway involves reduced toll-like receptor 4 (TLR4) signaling in microglia, potentially lowering neuroinflammatory cytokines including TNF-alpha and IL-6 [2]. These mechanistic hypotheses remain active research areas and are not yet confirmed by large phase III trials.

Who Can Prescribe LDN in Colorado

Any Colorado-licensed prescriber with Schedule II-V DEA registration may write an off-label LDN prescription. Naltrexone is not a controlled substance (DEA Schedule: unscheduled), which simplifies prescribing considerably compared with drugs like buprenorphine or testosterone [5].

Eligible prescriber types include:

• Physicians (MD or DO) holding a Colorado medical license
• Nurse practitioners (NPs) practicing under Colorado's full-practice-authority law (SB 18-108, enacted 2018), who may prescribe independently without physician supervision
• Physician assistants (PAs) operating under a signed collaboration agreement with a supervising Colorado physician

Colorado's full-practice-authority framework for NPs, codified at C.R.S. § 12-255-112, means that many telehealth platforms staffed primarily by NPs can legally issue LDN prescriptions without routing every chart through an MD co-signer. That structural feature expands access meaningfully, especially in rural counties like Costilla, Mineral, and Jackson where in-person specialist access is limited [6].

Prescribers are not required to have any specialty certification to write LDN. Pain medicine, rheumatology, neurology, integrative medicine, and family medicine physicians all prescribe it in routine practice. The only hard stop is an active opioid medication on the patient's medication list. Patients taking any full opioid agonist, including oxycodone, hydrocodone, morphine, or methadone, cannot safely start LDN without first completing opioid tapering and a 7 to 10 day washout period [5].

Getting LDN via Telehealth in Colorado

Colorado permits telehealth prescribing of non-controlled substances across state lines and within Colorado without the in-person visit requirement that applies to Schedule II controlled substances [7]. Because naltrexone is unscheduled, a Colorado-licensed telehealth provider can evaluate you via synchronous video, establish a valid patient-prescriber relationship during that visit, and send the LDN prescription electronically to a 503A compounder the same day.

The typical telehealth intake for LDN involves a structured medical history review covering autoimmune diagnoses, pain conditions, fatigue syndromes, and current medications. Most platforms also collect a symptom-severity questionnaire (often the Fibromyalgia Impact Questionnaire or a pain visual analog scale) at baseline to track response over 12 weeks [8].

After the video visit, the prescriber sends an electronic prescription to a 503A compounder licensed in Colorado. The compounder prepares the capsules, typically in a gelatin shell at the ordered dose (commonly 1.5 mg for the first 4 weeks, then 3.0 mg, then 4.5 mg), and ships directly to the patient's Colorado address. Standard turnaround from signed prescription to delivered product is 5, 7 business days for standard compounding and 3 to 5 days for pharmacies offering expedited production [9].

The HealthRX clinical team uses a three-phase titration framework for new LDN patients: Phase 1 (weeks 1, 4) at 1.5 mg nightly to assess tolerability; Phase 2 (weeks 5, 8) at 3.0 mg if no sleep disruption or GI side effects emerge; Phase 3 (week 9 onward) at 4.5 mg as the maintenance target. Patients who experience vivid dreams or insomnia on 4.5 mg are held at 3.0 mg long-term, since both doses fall within the therapeutic range studied in published trials.

Labs Required Before Starting LDN in Colorado

A complete metabolic panel (CMP) and complete blood count (CBC) are the minimum pre-treatment labs most Colorado prescribers order before initiating LDN. The CMP is required specifically to assess hepatic function. Naltrexone at standard 50 mg doses carries an FDA black-box warning for hepatotoxicity, though the clinical relevance of this warning at the sub-5 mg LDN dose range is debated [1]. The FDA label lists the hepatotoxicity warning based on older trial data at doses of 300 mg/day, roughly 60 to 200 times the LDN dose range [3].

Recommended pre-treatment lab panel:

• CMP (comprehensive metabolic panel): AST, ALT, and total bilirubin are the key hepatic markers. Most prescribers require AST and ALT below 3 times the upper limit of normal before initiating therapy.
• CBC with differential: Screens for cytopenias that could confound interpretation of any future immune-related side effects.
• Urine opioid drug screen: Confirms absence of full opioid agonists. Patients with buprenorphine or methadone on board cannot start LDN safely.
• TSH (thyroid-stimulating hormone): Recommended when the primary indication is fatigue, fibromyalgia, or autoimmune thyroid disease, because LDN is sometimes prescribed alongside thyroid hormone therapy.

Patients with abnormal baseline liver enzymes (ALT above 3x ULN) should have those values normalized or explained before starting. Published data on LDN and liver safety at therapeutic off-label doses are limited but reassuring in small cohorts. A 2014 open-label study in Crohn's disease patients (N=40) found no clinically significant change in hepatic enzymes over 12 weeks at 4.5 mg nightly [10].

Follow-up labs at 3 months are standard at most Colorado LDN practices: repeat CMP and a symptom-severity reassessment to determine whether the patient is responding and whether the dose should be adjusted.

Clinical Evidence Supporting LDN Use

Fibromyalgia

Younger and Mackey published a pilot crossover trial in Pain Medicine (2009) showing that LDN at 4.5 mg produced a 30% reduction in fibromyalgia symptom scores compared with placebo (P<0.05, N=10) [11]. The same research group followed with a larger placebo-controlled crossover trial (N=31) published in 2013, reporting a mean 28.8% reduction in pain scores on LDN versus 18.0% on placebo (P<0.05), with LDN also reducing mechanical sensitivity and improving general health satisfaction [8].

The Younger et al. 2013 trial is among the most-cited LDN studies and represents the strongest controlled evidence to date for fibromyalgia. It remains limited by sample size, which is why fibromyalgia is listed as "off-label" and why Colorado Medicaid does not cover LDN for this indication [12].

Multiple Sclerosis

Cree and colleagues published a 2010 placebo-controlled crossover trial in Annals of Neurology (N=80) examining LDN 4.5 mg in relapsing-remitting MS [13]. The primary outcome (Expanded Disability Status Scale score) did not show a statistically significant difference, but secondary outcomes including mental health composite scores and pain ratings favored LDN. The trial did not demonstrate disease modification, which means LDN should not replace disease-modifying therapies in MS patients.

Crohn's Disease

A pediatric pilot trial by Smith et al. (2011, N=40) found that 8 weeks of LDN 0.1 mg/kg (up to 4.5 mg) produced a response rate of 88% and remission in 25% of pediatric Crohn's patients, with no serious adverse events [14]. An adult follow-on open-label study by the same group confirmed the 12-week tolerability profile at 4.5 mg [10].

Chronic Pain and Neuroinflammation

Younger et al. (2009) examined low-dose naltrexone's central mechanism in a cohort study, demonstrating that LDN's anti-nociceptive effect appears to operate through microglial modulation rather than direct opioid receptor antagonism at these doses [11]. This mechanistic distinction matters clinically because it suggests LDN may benefit conditions driven by neuroinflammation even in opioid-naive patients.

What the Evidence Does Not Show

No phase III RCT with more than 200 participants has been completed for any LDN indication as of mid-2025. The absence of large-scale industry-sponsored trials reflects LDN's status as a generic, off-patent compound with no commercial manufacturer incentive to fund expensive registration studies [15]. Patients should understand that the evidence base, while promising, is built primarily on small trials and case series.

503A Compounding Pharmacies in Colorado: What You Need to Know

Every LDN prescription in Colorado is filled by a 503A compounding pharmacy. The "503A" designation comes from Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs pharmacies that compound medications for individual patient prescriptions. These differ from 503B outsourcing facilities, which compound in bulk without patient-specific prescriptions [3].

Colorado-licensed 503A pharmacies may:

• Compound naltrexone into oral capsules at any dose ordered by a licensed prescriber
• Ship compounded LDN to patients within Colorado under intrastate commerce rules
• Ship to out-of-state patients when permitted by the destination state's pharmacy board

Colorado's State Board of Pharmacy (DORA) licenses and inspects 503A compounders operating in the state. Patients selecting a compounding pharmacy should verify Colorado Board of Pharmacy licensure and look for additional accreditation from the Pharmacy Compounding Accreditation Board (PCAB), which requires adherence to USP chapters 795 (non-sterile) and 797 (sterile) standards [9].

Common capsule formulations available at Colorado 503A pharmacies include:

• Oral capsules in standard gelatin shells: 1.5 mg, 3.0 mg, 4.5 mg (most common)
• Sublingual troches: Less common, used when a patient has difficulty swallowing capsules
• Topical cream formulations: Occasionally prescribed for localized pain, though absorption data for topical naltrexone are very limited

Average cash-pay pricing at Colorado-area compounders runs $40, $90 per month for a 30-day supply of 4.5 mg capsules. Most insurance plans, including Colorado Medicaid and most commercial plans, do not cover compounded LDN for off-label indications [12].

Colorado Medicaid and Insurance Coverage for LDN

Colorado Medicaid does not cover compounded low-dose naltrexone for off-label indications including fibromyalgia, autoimmune conditions, chronic pain, or neuroinflammatory disorders. Coverage under Colorado's Medicaid program (Health First Colorado) is limited to FDA-approved drugs for FDA-approved indications, and no commercially manufactured LDN product holds FDA approval [12].

Commercial insurance coverage in Colorado is similarly unavailable for most patients. A small number of commercial plans may reimburse standard-dose naltrexone (50 mg) for addiction treatment, but compounded LDN capsules at sub-5 mg doses are universally excluded from formularies because they are not FDA-approved products.

Prior authorization is rarely a relevant concept for LDN in Colorado given that coverage is nearly always denied outright. When a prescriber does attempt prior authorization for a patient with an unusual plan structure, documentation typically required includes:

• Diagnosis code supporting the prescribed indication (e.g., M79.7 for fibromyalgia, G35 for MS, K50.90 for Crohn's)
• Attestation that FDA-approved first-line therapies were tried and failed or are contraindicated
• Published clinical literature supporting LDN for the specific indication
• Prescriber letter of medical necessity

This documentation standard mirrors what other state Medicaid programs require for off-label drug coverage, as outlined in CMS guidance on Medicaid drug coverage policy [15].

The practical reality for most Colorado patients: LDN is a cash-pay medication. At $40, $90/month, it is affordable relative to many specialty drugs, and the absence of insurance prior-authorization delays means some patients actually move faster to treatment than they would with a covered medication.

Transferring an Existing LDN Prescription to Colorado

Patients relocating to Colorado from another state can transfer their LDN prescription to a Colorado-licensed 503A pharmacy, provided the original prescribing state and Colorado both permit interstate dispensing of the compounded product. Because naltrexone is not a controlled substance, there are no DEA Schedule II transfer restrictions [5].

The practical steps for a prescription transfer are:

1. Request a written copy of the current LDN prescription from the out-of-state prescriber or pharmacy.
2. Identify a Colorado-licensed 503A pharmacy and confirm they compound the ordered dose and formulation.
3. Have the original prescriber fax or electronically transmit the prescription to the Colorado pharmacy.
4. If the original prescriber is not licensed in Colorado, a new Colorado-licensed prescriber must issue a new prescription after reviewing the patient's medical history. A telehealth visit typically satisfies this requirement.

Patients should plan for a 5, 10 business day gap in supply during the transfer process. Requesting the transfer 2 weeks before an existing supply runs out avoids missed doses.

Side Effects and Contraindications Relevant to Colorado Patients

LDN has a favorable tolerability profile in published trials. The most commonly reported side effects in the Younger et al. 2013 fibromyalgia crossover trial (N=31) were vivid dreams or sleep disturbances, reported by approximately 30% of participants during the first 4 weeks, most of which resolved spontaneously by week 6 [8].

Additional side effects reported across LDN trials include:

• Mild nausea during the titration phase (most common in weeks 1, 2 at 1.5 mg)
• Headache (reported in roughly 10 to 15% of participants in published trials)
• Fatigue paradoxically worsening in the first 1 to 2 weeks before improving
• Rare reports of increased anxiety, which may reflect opioid receptor sensitivity in patients with high baseline endogenous opioid tone

Absolute contraindications for LDN:

• Current use of any full opioid agonist (oxycodone, hydromorphone, morphine, fentanyl, methadone, codeine, tramadol)
• Acute opioid withdrawal state
• Known hypersensitivity to naltrexone or any component of the compounded capsule

Relative contraindications requiring clinical judgment:

• Buprenorphine use (partial agonist): LDN can precipitate withdrawal; a 7 to 14 day washout from buprenorphine is required before starting [5]
• Active hepatic disease with AST or ALT above 3x ULN
• Pregnancy: Naltrexone is FDA Pregnancy Category C; animal data show fetal risk at high doses; risk at LDN doses is unknown [1]

Patients on naltrexone-containing medications for addiction treatment (ReVia 50 mg, Vivitrol 380 mg IM) should not also take LDN, as the mechanism is dose-dependent and the combination does not provide additive benefit [3].

How Long Before LDN Works

Clinical response timelines from published trials suggest most patients who respond to LDN notice improvement between weeks 4 and 12 of consistent nightly dosing [8] [11]. The Younger 2013 fibromyalgia trial ran 12 weeks per treatment arm and showed statistically significant pain reduction by week 8 in the active-treatment group.

A 12-week trial period at therapeutic dose (4.5 mg for at least 8 of the 12 weeks) is the standard clinical threshold most Colorado LDN prescribers use before declaring a patient a non-responder. Stopping earlier than 8 weeks on therapeutic dose does not provide a fair evaluation of efficacy, particularly for autoimmune and neuroinflammatory indications where the immunomodulatory mechanism may require sustained receptor sensitization [2].

Patients who see no improvement after 16 weeks of consistent 4.5 mg nightly dosing and verified adherence are generally tapered off LDN and reassessed for alternative diagnoses or treatments. No evidence supports dose escalation beyond 4.5 mg for the indications currently studied [13].

Starting LDN with HealthRX in Colorado

Colorado residents can complete the initial LDN consultation with a HealthRX-affiliated prescriber via a HIPAA-compliant video visit, typically 20 to 30 minutes. The prescriber reviews medical history, current medications, and relevant prior workup, then orders any missing pre-treatment labs through a Colorado lab draw site if needed.

Lab results are reviewed asynchronously, and the LDN prescription is sent electronically to a PCAB-accredited 503A compounder serving Colorado. Most patients receive their first 30-day supply within 5, 7 business days of the completed lab review.

Follow-up visits occur at 4 weeks (dose titration assessment), 8 weeks (tolerability and early efficacy), and 12 weeks (full response evaluation with repeat CMP). Patients demonstrating a response at 12 weeks are continued on LDN with quarterly check-ins and annual lab review.

The starting dose for all new HealthRX Colorado patients is 1.5 mg nightly for the first 28 days, consistent with the titration approach used in the Younger et al. 2013 protocol [8].